Sophie Postel-Vinay
#28,725
Most Influential Person Now
French researcher, oncologist
Sophie Postel-Vinay's AcademicInfluence.com Rankings
Sophie Postel-Vinaymedical Degrees
Medical
#906
World Rank
#1169
Historical Rank
Oncology
#98
World Rank
#102
Historical Rank
Sophie Postel-Vinayphilosophy Degrees
Philosophy
#11637
World Rank
#16062
Historical Rank
Logic
#8437
World Rank
#10558
Historical Rank
Download Badge
Medical Philosophy
Sophie Postel-Vinay's Degrees
- PhD Oncology Université Paris Cité
Why Is Sophie Postel-Vinay Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sophie Postel-Vinay is a French physician and scientist at the Institut Gustave Roussy where she has led an ATIP-Avenir team since 2018. She works on oncology and the development of new drugs and is an expert in early clinical trials. She was the 2019 winner of the Irène Joliot-Curie Prize in the “young woman scientist” category.
Sophie Postel-Vinay's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016) (1560)
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 (2016) (889)
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. (2017) (465)
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. (2017) (411)
- Targeting FGFR Signaling in Cancer (2015) (354)
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. (2010) (315)
- Rationale for anti-OX40 cancer immunotherapy. (2016) (235)
- Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise (2019) (200)
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer (2019) (183)
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. (2020) (181)
- Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma (2012) (159)
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers (2016) (154)
- Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? (2011) (128)
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). (2017) (112)
- Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo (2014) (109)
- The potential of exploiting DNA-repair defects for optimizing lung cancer treatment (2012) (101)
- Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial (2016) (95)
- Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines (2016) (92)
- Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. (2016) (89)
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. (2016) (86)
- Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey (2017) (86)
- BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation (2019) (82)
- Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation (2018) (79)
- The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study (2010) (79)
- Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? (2010) (76)
- A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer (2013) (71)
- Targeting the DNA damage response in immuno-oncology: developments and opportunities (2021) (70)
- Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? (2009) (67)
- Epigenetic modifiers as new immunomodulatory therapies in solid tumours (2018) (61)
- Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. (2019) (57)
- Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. (2014) (56)
- Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. (2016) (55)
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. (2016) (54)
- First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. (2019) (53)
- TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma (2018) (53)
- Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial (2017) (51)
- Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors (2016) (49)
- Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) (2018) (48)
- Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients (2015) (46)
- Reovirus: Rationale and clinical trial update. (2009) (43)
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours (2020) (41)
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. (2018) (41)
- Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. (2020) (40)
- PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer (2021) (40)
- ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform (2013) (38)
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors (2017) (38)
- Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) (2019) (37)
- Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers (2016) (37)
- Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). (2017) (33)
- AXL and acquired resistance to EGFR inhibitors (2012) (29)
- P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC (2017) (24)
- Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study (2021) (23)
- JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. (2017) (22)
- Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types (2020) (22)
- Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers (2018) (22)
- Beyond DNA repair: the novel immunological potential of PARP inhibitors (2019) (21)
- First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. (2017) (21)
- Exploiting epigenetic vulnerabilities in solid tumors: novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. (2020) (18)
- Chromatin Regulators as a Guide for Cancer Treatment Choice (2016) (18)
- In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? (2017) (18)
- Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germlineBRCA-mutated (gBRCAm) metastatic breast cancer (MBC) (2019) (17)
- ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer. (2017) (17)
- Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. (2018) (16)
- ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors. (2016) (16)
- DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade (2018) (16)
- Clinical benefit of early phase clinical trial participation for advanced sarcoma patients (2011) (16)
- Patient-reported tolerability of adverse events in phase 1 trials (2017) (16)
- Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients (2014) (16)
- Clinical benefit in phase I trials of novel molecularly targeted agents: Does dose matter? (2008) (15)
- Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) (2020) (15)
- Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. (2018) (15)
- First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies (2016) (14)
- Modifying phase I methodology to facilitate enrolment of molecularly selected patients. (2013) (13)
- Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee. (2014) (13)
- Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments (2022) (12)
- Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. (2020) (12)
- Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing? (2016) (11)
- Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (11)
- Phase I trials in oncology: a new era has started. (2015) (10)
- Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers (2018) (10)
- Phase I-II trial designs: how early should efficacy guide the dose recommendation process? (2018) (10)
- Patterns of progression in patients treated for immuno-oncology antibodies combination (2020) (10)
- Impact of COVID-19 Pandemic on Cancer Research (2020) (9)
- 1081O_PRPROFESSIONAL BURNOUT IN EUROPEAN YOUNG ONCOLOGISTS: A EUROPEAN SURVEY CONDUCTED BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) YOUNG ONCOLOGISTS COMMITTEE (2014) (9)
- Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1) (2016) (8)
- Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. (2016) (8)
- Phase I trials in oncology: a new era has started. (2015) (8)
- Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? (2018) (8)
- Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma (2017) (8)
- Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression? (2013) (8)
- Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? (2020) (7)
- Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. (2018) (7)
- Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions. (2022) (7)
- Redefining dose-limiting toxicity. (2015) (7)
- Understanding genetic determinants of resistance to immune checkpoint blockers. (2019) (6)
- A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials (2016) (6)
- Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers (2022) (6)
- How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma? (2019) (6)
- Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients (2016) (5)
- Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts (2019) (5)
- Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors (2015) (5)
- Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. (2018) (5)
- 388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma (2008) (4)
- Chemotherapy for poor prognosis non seminomatous germ cell tumors (NSGCT): Should doses be reduced at first cycle to prevent acute respiratory distress syndrome (ARDS) in patients with multiple lung metastases? (2007) (4)
- Identification of new prognostic factors in phase I patients treated by immunotherapy (2016) (4)
- Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. (2018) (4)
- Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1? (2010) (4)
- Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience (2016) (4)
- BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial (2022) (3)
- Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience. (2010) (3)
- Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. (2022) (3)
- Evaluation of PFS ratio in patients with cancer enrolled in early-phase clinical trials: A single center, retrospective analysis. (2017) (3)
- 1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT) (2020) (3)
- 100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial (2021) (3)
- 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer (2021) (3)
- Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials (2018) (2)
- Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts (2021) (2)
- [Dose finding methods for targeted agents: new perspectives]. (2010) (2)
- Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial (2015) (2)
- Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygousMTAPdeletion (2019) (2)
- 125OFirst-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors (2015) (2)
- Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs). (2018) (2)
- Dose-exposure-response relationship between AZD6738 and peripheral monocytes. (2017) (2)
- 301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors (2015) (2)
- Preliminary results of an open-label phase I pharmacokinetic/pharmacodynamic study of JNJ26481585: Early evidence of antitumor activity. (2016) (2)
- Abstract 1058: Targeting chromatin remodeling-associated genetic vulnerabilities in cancer: PBRM1 defects are synthetic lethal with PARP and ATR inhibitors (2020) (2)
- Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. (2022) (2)
- Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer (2021) (1)
- 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis (2021) (1)
- Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system (2014) (1)
- Preclinical Data and Requirements (2015) (1)
- Lorlatinib in ALK-or ROS 1-rearranged non-small cell lung cancer : an international , multicenter , open-label phase 1 trial (2018) (1)
- Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? (2018) (1)
- Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic (2021) (1)
- A Novel Synthetic Lethal Approach to Target MYC-Driven Cancers. (2022) (1)
- 1381TiPA randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial (2017) (1)
- The BAP1 deubiquitinase complex is a general transcriptional co-activator (2018) (1)
- 508P High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors (2022) (1)
- Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. (2022) (1)
- Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial. (2018) (1)
- 47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs (2020) (0)
- Abstract CT201: Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors (2022) (0)
- Abstract CT029: The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors (2016) (0)
- Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors. (2015) (0)
- Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. (2018) (0)
- 349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents (2015) (0)
- Profile and Outcome of Cancer Patients enrolled in Contemporary Phase I Trials (2023) (0)
- 319 Risk factors of screen-failures in phase 1 clinical trials (2015) (0)
- Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. (2023) (0)
- NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear–mitochondrial crosstalk in ERCC1-deficient populations (2016) (0)
- Abstract 617: High-throughput screens identify PARP inhibition as being synthetically lethal with ERCC1 deficiency in non-small cell lung cancer cell lines. (2013) (0)
- Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials (2016) (0)
- Abstract P2-13-02: COBRA: Characteristics and Outcomes of patients with BReast cancer in phAse I trials at Gustave Roussy Cancer center (2023) (0)
- 109O Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors (2023) (0)
- 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)? (2023) (0)
- 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials (2023) (0)
- 456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors (2022) (0)
- 324 Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports (2015) (0)
- 1672P Tumor and immune cell dynamics at single-cell resolution on combined PARP inhibition and anti-PD-L1 therapy (2022) (0)
- EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors (2022) (0)
- 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC) (2022) (0)
- Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer (2013) (0)
- Abstract 5006: Docetaxel-platinum-fluorouracil (TPF) induction chemotherapy increases PD-L1 positivity and CD8+ / FOXP3+ immune infiltrates in advanced head and neck squamous cell carcinoma (HNSCC) (2016) (0)
- Overall survival prognosis of patients in immuno-oncology phase I trials: The Gustave Roussy score. (2017) (0)
- 288 Synthetic Lethality in ERCC1-deficient Non-Small Cell Lung Cancer (2012) (0)
- PBRM1 deficiency in cancer is synthetic lethal with DNA repair inhibitors (2020) (0)
- Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials. (2018) (0)
- 472P Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials (2022) (0)
- 2631 Inclusion of patients with urothelial bladder cancer in phase 1 trials: What is the impact? (2015) (0)
- 141PSelf-questionnaire to assess patient’s preferences for participation in phase I clinical trials (2018) (0)
- NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear-mitochondrial crosstalk in ERCC1-deficient populations. (2017) (0)
- Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations (2016) (0)
- First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) (2023) (0)
- Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups. (2018) (0)
- Abstract 6277: Identification of ATR inhibitors as therapeutic opportunities in Desmoplastic small round cell tumors (2022) (0)
- 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic (2021) (0)
- [Cancer and spirituality: the young oncologists' point of view]. (2009) (0)
- Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
- Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies? (2016) (0)
- Development of Immunotherapeutic Strategies for Early Phase Clinical Trials (2020) (0)
- 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study (2022) (0)
- 1165P Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas (2017) (0)
- 1168PEstimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq (2017) (0)
- [Exploiting DNA repair vulnerabilities with PARP inhibitors to stimulate anti-tumor immunity]. (2019) (0)
- Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. (2016) (0)
- Immune Therapies in Phase 1 Trials (2018) (0)
- 1163PImmunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience (2017) (0)
- Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. (2018) (0)
- 1159PLong term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation (2017) (0)
- Dysregulation of FGFR Signaling in Human Malignancies (2015) (0)
- 1703PDLandscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials (2017) (0)
- 9P Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials (2021) (0)
- Patient selection criteria for PHASE-I trials in oncology: Low lymphocyte counts are associated with poor survival (2008) (0)
- Abstract LB-129: Epigenetic regulators to predict docetaxel sensitivity; a guide for treatment choice (2016) (0)
- Profiles of screen-failures in phase 1 clinical trials. (2015) (0)
- You BETer be aware – learnings from a negative Phase 1 study (2019) (0)
- Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers (2022) (0)
- Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors. (2022) (0)
- Abstract 5714: Characterization of SWI/SNF complex gene mutations, protein expression and tumor immune microenvironment in cholangiocarcinoma (2022) (0)
- SP-0258: Potentiation of anti-tumor immune effects by PARP Inhibitors (2020) (0)
- 1632PDA novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1 (2017) (0)
- Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (2018) (0)
- Abstract CT031: The effect of food on the pharmacokinetics (pk) of tazemetostat in patients with cancer (2016) (0)
This paper list is powered by the following services:
Other Resources About Sophie Postel-Vinay
What Schools Are Affiliated With Sophie Postel-Vinay?
Sophie Postel-Vinay is affiliated with the following schools:
